Edition:
United Kingdom

Global Blood Therapeutics Inc (GBT.OQ)

GBT.OQ on NASDAQ Stock Exchange Global Select Market

62.95USD
16 Feb 2018
Change (% chg)

$-0.70 (-1.10%)
Prev Close
$63.65
Open
$62.95
Day's High
$64.10
Day's Low
$62.00
Volume
130,117
Avg. Vol
258,141
52-wk High
$65.40
52-wk Low
$22.75

Chart for

About

Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD). The... (more)

Overall

Beta: --
Market Cap(Mil.): $1,412.94
Shares Outstanding(Mil.): 43.68
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 83.93 16.64
EPS (TTM): -- -- --
ROI: -- 1.66 10.66
ROE: -- 2.58 14.30

BRIEF-GBT Receives Fda Breakthrough Therapy Designation For Voxelotor For Treatment Of Sickle Cell Disease

* GBT RECEIVES FDA BREAKTHROUGH THERAPY DESIGNATION FOR VOXELOTOR FOR TREATMENT OF SICKLE CELL DISEASE (SCD) Source text for Eikon: Further company coverage:

09 Jan 2018

BRIEF-Global Blood Therapeutics Prices A $100.0 Mln Common Stock Public Offering

* GLOBAL BLOOD THERAPEUTICS PRICES A $100.0 MILLION COMMON STOCK PUBLIC OFFERING Source text for Eikon: Further company coverage:

15 Dec 2017

BRIEF-Global Blood Therapeutics To Sell $100 Mln In Public Offering Of Shares

* GLOBAL BLOOD THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

14 Dec 2017

BRIEF-Global Blood Therapeutics says DSMB safety review for phase 3 HOPE study completed

* Global Blood Therapeutics announces completion of safety review by independent data and safety monitoring board (DSMB) for phase 3 HOPE study in sickle cell disease Source text for Eikon: Further company coverage:

13 Nov 2017

BRIEF-Global Blood Therapeutics posts Q3 loss per share $0.66

* Global Blood Therapeutics reports recent business progress and provides third quarter 2017 financial results

02 Nov 2017

BRIEF-Global blood Therapeutics reports approval of voxelotor as nonproprietary name for GBT440

* Global Blood Therapeutics announces approval of first-in-class “voxelotor” as nonproprietary name for gbt440

24 Oct 2017

BRIEF-Global Blood Therapeutics announces discontinuation of IPF program

* Global Blood Therapeutics announces discontinuation of Idiopathic Pulmonary Fibrosis (IPF) program​

23 Oct 2017

BRIEF-Point72 Asset Management LP reports 5.2 pct passive stake in Global Blood Therapeutics

* Point72 Asset Management LP reports 5.2 percent passive stake in Global Blood Therapeutics Inc ‍​as of October 2 - SEC filing Source text: (http://bit.ly/2yH9e9Y) Further company coverage:

03 Oct 2017

BRIEF-Global Blood Therapeutics receives rare pediatric disease designation from FDA for GBT440 for treatment of sickle cell disease

* Global Blood Therapeutics receives rare pediatric disease designation from FDA for GBT440 for treatment of sickle cell disease (scd) Source text for Eikon: Further company coverage:

05 Sep 2017

Competitors

  Price Chg
Bristol-Myers Squibb Co (BMY.N) $68.96 -0.02
Bristol-Myers Squibb Co (BMYMP.PK) $1,042.55 --
Novartis AG (NOVN.S) CHF79.68 -1.12
bluebird bio Inc (BLUE.OQ) $213.35 +4.70
Pfizer Inc. (PFE.N) $36.26 +0.55
Roche Holding Ltd. (ROG.S) CHF223.15 -2.35
Roche Holding Ltd. (RO.S) CHF226.00 -4.20

Earnings vs. Estimates